Is Aimovig (erenumab) considered a controlled substance?
No. Aimovig (erenumab) is a prescription medicine for migraine prevention and is not classified as a controlled substance under U.S. federal controlled-substance schedules.
What is Aimovig used for, and why that matters for “controlled substance” status
Aimovig is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) pathway to prevent migraines. Controlled-substance rules generally apply to drugs with abuse potential (such as opioids, certain sedatives, and stimulants), and Aimovig is not in that category.
Can it still be restricted by doctors or pharmacies?
Yes, but not because it is controlled. Like many specialty migraine treatments, Aimovig can face prescribing and dispensing limits such as prior authorization, step therapy, and insurer requirements. These are coverage-management rules, not controlled-substance laws.
Are there any exceptions or country-to-country differences?
Controlled-substance status can vary by country, but Aimovig is not typically listed as a scheduled drug in the way opioids and other high-abuse-potential medications are. If you tell me your country (and state/province if relevant), I can help you narrow down how it is regulated where you live.
Source
I didn’t find a DrugPatentWatch.com listing relevant to “controlled substance” classification for Aimovig in the provided materials. If you want, share what country you’re asking about and I can tailor the answer to the applicable regulatory system.